kloh-PID-oh-grel 
Absorption: Well absorbed following oral administration; rapidly metabolized to an active antiplatelet compound. Parent drug has no antiplatelet activity.
Distribution: Unknown.
Protein Binding: Clopidogrel — 98%; active metabolite — 94%.
Metabolism/Excretion: Rapidly and extensively converted by the liver (CYP2C19) to its active metabolite, which is then eliminated 50% in urine and 45% in feces;2% of Whites, 4% of Blacks, and 14% of Asians have CYP2C19 genotype that results in reduced metabolism of clopidogrel (poor metabolizers) into its active metabolite (may result in ↓ antiplatelet effects).
Half-life: 6 hr (active metabolite 30 min).
Contraindicated in:
Use Cautiously in:
Incidence of adverse reactions similar to that of aspirin
CV: chest pain, edema, hypertension.
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, pruritus, purpura, rash.
EENT: epistaxis.
GI: GI BLEEDING, abdominal pain, diarrhea, dyspepsia, gastritis.
Hemat: BLEEDING, NEUTROPENIA, THROMBOTIC THROMBOCYTOPENIC PURPURA.
Metab: hypercholesterolemia.
MS: arthralgia, back pain.
Neuro: depression, dizziness, fatigue, headache.
Resp: cough, dyspnea, eosinophilic pneumonia.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), fever.
Drug-Drug:
Drug-Natural Products:
Recent MI, Stroke, or Peripheral Arterial Disease
Acute Coronary Syndrome
Therapeutic Classification: antiplatelet agents
Pharmacologic Classification: platelet aggregation inhibitors
NDC Code*
